Related Experiment Video

Updated: Nov 11, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K

CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer

Xue Ying1, Xuan Che1,2, Jianzhang Wang1

  • 1Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China, 310006.

Journal of Cancer
|March 24, 2021
PubMed

Insights

Cyclin-dependent kinase 1 (CDK1) promotes endometrioid endometrial cancer growth. Inhibiting CDK1 induces apoptosis and halts cancer progression, identifying CDK1 as a potential therapeutic target for this malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gynecologic Oncology

Background:

  • Endometrial cancer (EC) is a prevalent gynecologic malignancy globally.
  • Identifying novel therapeutic targets is crucial for improving patient outcomes in endometrioid EC.
  • CDK1 emerged as a key gene in EC pathogenesis through bioinformatic analysis.

Purpose of the Study:

  • To investigate the role of CDK1 in endometrioid endometrial cancer.
  • To evaluate CDK1 as a potential therapeutic target for EC.

Main Methods:

  • Bioinformatic analysis to identify hub genes.
  • Immunohistochemistry to assess CDK1 expression in EC tissues.
  • In vitro cell assays (viability, colony formation, apoptosis, cell cycle) to determine CDK1's functional role.
  • In vivo xenograft models to evaluate therapeutic efficacy.

Main Results:

  • CDK1 is overexpressed in endometrioid EC, with cytoplasmic accumulation correlating with histological grade.
  • CDK1 promotes EC cell proliferation and colony formation in vitro.
  • CDK1 inhibition leads to apoptosis and G2/M cell cycle arrest in EC cells.
  • Inhibition of CDK1 suppresses tumor growth in vivo.

Conclusions:

  • CDK1 plays a significant role in the pathogenesis of endometrioid endometrial cancer.
  • CDK1 represents a promising novel therapeutic target for endometrioid EC treatment.
Keywords:
CDK1RO3306bioinformatics analysisendometrial cancertargeted therapy

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.0K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.1K
S-Cdk Initiates DNA Replication02:38

S-Cdk Initiates DNA Replication

The cell cycle is a series of events leading to DNA duplication followed by the division of cell content to form two daughter cells. The cell cycle progresses in four stages—the cell increases in size (gap 1 or G1-phase), duplicates its DNA (synthesis or S-phase), prepares to divide (gap 2 or G2-phase), and divides (mitosis or M-phase).
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
5.1K